Can PCI outcomes get any better?

This is a case-based discussion on how DynamX Bioadaptor improves patients' clinical outcomes in real life. Also the faculty will delve into the current unmet long-term needs in PCI with DES.

They will also discuss the 2 year findings of the Bioadaptor RCT trial and 1 year findings of INFINITY SWEDEHEART trial and provide their perspective on the clinical implications of these findings and potential impact on the future of PCI in light of the outcomes.

1-year outcomes from INFINITY-SWEDEHEART RCT recently presented at ESC 2024 demonstrated that DynamX Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after 6 months.

Learn more about INFINITY-SWEDEHEART outcomes

Chairwoman
Rasha Al-Lamee, London, United Kingdom

Speakers
Johan Bennett, Leuven, Belgium
Davide Capodanno, Catania, Italy
David Erlinge, Lund, Sweden
Teguh Santoso, Jakarta, Indonesia